SOUTH SAN FRANCISCO, CA, Sep. 11, 2009 (Marketwire) --
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/11/09 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to host a Research and Development Day on Friday, September 18, 2009. The event is scheduled to take place from 8:00 - 10:00am Eastern Time at the New York Grand Hyatt Hotel in New York, New York and be simultaneously webcast.
Those interested in attending in person should RSVP to investor@cytokinetics.com by September 14th. In addition, parties may access the live audio webcast of this presentation and accompanying slides by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com. The live audio of the forum will also be accessible by dialing either (866) 999-2985 (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 28892340. The webcast replay of the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website following the event. The replay will also be available via telephone from September 18, 2009 at 12:00 p.m. Eastern Time until September 30, 2009 by dialing (800) 642-1687 (United States and Canada) or (706) 645-9291 (International) and typing in the passcode 28892340.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, omecamtiv mecarbil (formerly CK-1827452), a novel small molecule cardiac muscle myosin activator, is in Phase II clinical trials for the potential treatment of heart failure. In May 2009, Amgen Inc. exercised an option to obtain an exclusive worldwide (excluding Japan) license to develop and commercialize omecamtiv mecarbil and related compounds. Under the parties' collaboration agreement, Amgen has assumed responsibility for development and commercialization of omecamtiv mecarbil and related compounds, at its expense, subject to specified development and commercialization participation rights of Cytokinetics. In June 2009, Cytokinetics initiated a Phase I clinical trial of CK-2017357, a fast skeletal muscle troponin activator, in healthy volunteers in the United States. CK-2017357 is being developed as a potential treatment for diseases and medical conditions associated with aging, muscle wasting, and neuromuscular dysfunction. In January 2009, Cytokinetics announced the selection of a potential drug candidate directed towards smooth muscle contractility.
